TSG Advice Partners’s AbbVie ABBV Stock Holding History

TSG Advice Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.27M	Buy	5,826 +3,036	+109%	+$673K	0.19%	42
2025 Q4	$638K	Buy	+2,790	New	+$636K	0.1%	56

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSG Advice Partners's ABBV Position: Q1 2026 in Review

TSG Advice Partners increased its AbbVie (ABBV) stake by 109% in Q1 2026, buying an estimated $673K and bringing the position to 5,826 shares worth $1.27M. The position accounts for 0.19% of the portfolio, ranked #42.

TSG Advice Partners first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,098 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

TSG Advice Partners held 5,826 shares of AbbVie worth $1.27M as of Q1 2026.
TSG Advice Partners bought 3,036 AbbVie shares in Q1 2026, an estimated $673K.
AbbVie made up 0.19% of TSG Advice Partners's portfolio in Q1 2026, its #42 holding.
TSG Advice Partners first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
4,098 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on TSG Advice Partners's 13F filing for Q1 2026, filed 24 Apr 2026.